Biostage Stock Number Of Shares Shorted

Biostage fundamentals help investors to digest information that contributes to Biostage's financial success or failures. It also enables traders to predict the movement of Biostage OTC Stock. The fundamental analysis module provides a way to measure Biostage's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostage otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Biostage OTC Stock Number Of Shares Shorted Analysis

Biostage's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Shares Shorted

 = 

Shorted by Public

+

by Institutions

More About Number Of Shares Shorted | All Equity Analysis

Current Biostage Number Of Shares Shorted

    
  121.66 K  
Most of Biostage's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition

Based on the recorded statements, Biostage has 121.66 K of outstending shares currently sold short by investors. This is 96.2% lower than that of the Biotechnology sector and 97.61% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 97.41% higher than that of the company.

Did you try this?

Run Headlines Timeline Now

   

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Biostage Fundamentals

Currently Active Assets on Macroaxis

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Biostage OTC Stock

If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios


 

Trending Assets

CVALF
Covalon Technologies
1.66  -0.1  -5.68 
CMVLF
Cellectis SA
1.25  0.00  0.00 
PRNAF
Alterity Therapeutics
0.01  0.00  0.00 
CPMV
Mosaic Immunoengineering
0.98  0.01  1.03 
News Freq…Investor S…